Bolstered by the success of the psilocybin trial in AIDS survivors, UCSF researchers began investigating psychedelics for a variety of disorders. Woolley launched the Translational Psychedelic Research (TrPR, pronounced “tripper”) Program, a consortium of UCSF researchers that is now investigating psilocybin as a treatment for eating disorders, for depression in people with bipolar disorder, and even for chronic low back pain. Because so much of pain is about perception, the researchers hypothesize, psychedelics might help patients learn to manage their pain with less emotional suffering.
In collaboration with the UCSF Movement Disorders Center, TrPR is also testing psilocybin for depression and anxiety in Parkinson’s patients — the first-ever trial in the U.S. to use a psychedelic for a neurodegenerative disorder. Previous studies suggest that psilocybin and LSD create long-term changes in cognitive function and coping strategies. They may also enhance the brain’s ability to acquire new information and make new connections, functions that are often impaired by depression and other neuropsychiatric disorders. For this reason, researchers believe these drugs could be most useful for treating conditions related to existential distress, addiction, or being stuck in certain ways of thinking.
The decision to study Parkinson’s — a degenerative brain disorder marked by uncontrollable movements, loss of coordination, and difficulty with balance — may seem puzzling. But “Parkinson’s is like an iceberg,” says Ellen Bradley, M.D., who is leading the trial, which will end early this year. “Motor features are above the water, but there’s this giant part that’s invisible but impactful for functioning.” Depression and anxiety, in particular, plague many people with Parkinson’s, but such patients don’t tend to respond well to antidepressant or antianxiety medications.
B 1 therapy for Parkinson’s 
Red Light Therapy Pad
Stem Cell therapy for PD
PEMF mat therapy update
Red Light Therapy - Coronase 
